Introduction: As the coronavirus disease 2019 (COVID-19) pandemic continues
to spread on an unprecedented scale from around the world, we described our
experience in treating early COVID-19 cases in India. Materials and Methods: An
observational study of COVID-19 patients admitted to a tertiary care centre in
North India between 2 March–4 April 2020 was performed. The clinical,
epidemiological, laboratory, treatment and outcome data of patients were
evaluated. Results: A total of 75 patients were treated and 56 (74.66%) were men.
The clinical spectrum of COVID-19 ranged from asymptomatic to acute respiratory
distress syndrome (ARDS). Fever (85.36%) was the most common symptom followed
by cough (56.09%) and dyspnoea (19.51%). Findings from hemogram analysis
showed that 32%, 21.33% and 18.67% of patients had lymphopaenia, eosinopenia
and thrombocytopaenia, respectively. Inflammatory markers such as C-reactive
protein, D-dimer, ferritin, fibrin degradation product and interleukin-6 were
significantly elevated (P <0.05) in patients who required oxygen therapy than those
who did not require it, suggesting the potential role such markers could play in
predicting prognosis in patients. Mean hospital stay was 9.2 days and 72 (96%)
patients made a complete recovery, but 3 (4%) patients demised after progressing
to ARDS. Conclusion: The clinical and epidemiological spectrum of COVID-19 has
jeopardised the health system in India. Without a proven therapy to combat this
pandemic and with no sight of vaccines in the near future, a preventive strategy
should be adopted to contain the spread of this infectious disease.
Key words: Acute respiratory distress syndrome, Cytokine release syndrome,
Interleukin-6, Lopinavir-ritonavir, Lymphopaenia